Survival rates of familial and sporadic prostate cancer patients
To compare cancer-specific survival rates for familial and sporadic prostate cancer patients. Gleason score and age at diagnosis of familial group and sporadic group were compared by χ(2) and t-test. Cancer-specific survival rates were analyzed by the Kaplan - Meier method and compared by log-rank t...
Gespeichert in:
| Veröffentlicht in: | Experimental oncology 2015-06, Vol.37 (2), p.154-155 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 155 |
|---|---|
| container_issue | 2 |
| container_start_page | 154 |
| container_title | Experimental oncology |
| container_volume | 37 |
| creator | Plonis, J Nakazawa-Miklasevica, M Malevskis, A Vaganovs, P Pildava, S Vjaters, E Gardovskis, J Miklasevics, E |
| description | To compare cancer-specific survival rates for familial and sporadic prostate cancer patients.
Gleason score and age at diagnosis of familial group and sporadic group were compared by χ(2) and t-test. Cancer-specific survival rates were analyzed by the Kaplan - Meier method and compared by log-rank test. Statistically significant level was set at p < 0.05.
Among 1175 prostate cancer patients, familial group consisted of 215 (18.3%) patients, the sporadic group consisted of 960 (81.7%) patients. The familial group patient's mean age at diagnosis (58.9 years old, 95% confidence interval (CI) 57.8-60.1) was significantly younger than that of sporadic group patients (67.2 years old, 95% CI 66.7-67.6) (p < 0.0001). Comparing Gleason score between familial group and sporadic group revealed no statistically significant difference. The analysis showed that 92% (95% CI 0.88-0.97) of familial group patients had a 10-year cancer-specific survival rates, which was a significantly better outcome than that of sporadic group with 69% (95% CI 0.60-0.78) 10-year cancer-specific survival rates (p = 0.0237).
The study data demonstrate statistically significant difference between familial group and sporadic group concerning age and cancer-specific survival rates, but not Gleason score. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1691593889</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1691593889</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-a48192ed17855efe3894c39087f70314c2775ec92fe7c62c100587df9b48f92f3</originalsourceid><addsrcrecordid>eNo1j8tKBDEURLNQnHH0FyRLNw15J3enDL5gwIW6bjLpG4j0yyQ94N_boK4KDoei6oxsueOiAWFgQy5L-WTMaDDqgmyE4VyAMlty97bkUzr5nmZfsdAp0uiH1KeV-LGjZZ6y71Kgc55KXRUa_Bgw09nXhGMtV-Q8-r7g9V_uyMfjw_v-uTm8Pr3s7w_NzIWpjVeOg8COW6c1RpQOVJDAnI2WSa6CsFZjABHRBiMCZ0w720U4KhdXKnfk9rd3HfK1YKntkErAvvcjTktpuQGuQToHq3rzpy7HAbt2zmnw-bv9fy1_ADhjUcc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1691593889</pqid></control><display><type>article</type><title>Survival rates of familial and sporadic prostate cancer patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Plonis, J ; Nakazawa-Miklasevica, M ; Malevskis, A ; Vaganovs, P ; Pildava, S ; Vjaters, E ; Gardovskis, J ; Miklasevics, E</creator><creatorcontrib>Plonis, J ; Nakazawa-Miklasevica, M ; Malevskis, A ; Vaganovs, P ; Pildava, S ; Vjaters, E ; Gardovskis, J ; Miklasevics, E</creatorcontrib><description>To compare cancer-specific survival rates for familial and sporadic prostate cancer patients.
Gleason score and age at diagnosis of familial group and sporadic group were compared by χ(2) and t-test. Cancer-specific survival rates were analyzed by the Kaplan - Meier method and compared by log-rank test. Statistically significant level was set at p < 0.05.
Among 1175 prostate cancer patients, familial group consisted of 215 (18.3%) patients, the sporadic group consisted of 960 (81.7%) patients. The familial group patient's mean age at diagnosis (58.9 years old, 95% confidence interval (CI) 57.8-60.1) was significantly younger than that of sporadic group patients (67.2 years old, 95% CI 66.7-67.6) (p < 0.0001). Comparing Gleason score between familial group and sporadic group revealed no statistically significant difference. The analysis showed that 92% (95% CI 0.88-0.97) of familial group patients had a 10-year cancer-specific survival rates, which was a significantly better outcome than that of sporadic group with 69% (95% CI 0.60-0.78) 10-year cancer-specific survival rates (p = 0.0237).
The study data demonstrate statistically significant difference between familial group and sporadic group concerning age and cancer-specific survival rates, but not Gleason score.</description><identifier>ISSN: 1812-9269</identifier><identifier>PMID: 26112946</identifier><language>eng</language><publisher>Ukraine</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Prostatic Neoplasms - mortality</subject><ispartof>Experimental oncology, 2015-06, Vol.37 (2), p.154-155</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26112946$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Plonis, J</creatorcontrib><creatorcontrib>Nakazawa-Miklasevica, M</creatorcontrib><creatorcontrib>Malevskis, A</creatorcontrib><creatorcontrib>Vaganovs, P</creatorcontrib><creatorcontrib>Pildava, S</creatorcontrib><creatorcontrib>Vjaters, E</creatorcontrib><creatorcontrib>Gardovskis, J</creatorcontrib><creatorcontrib>Miklasevics, E</creatorcontrib><title>Survival rates of familial and sporadic prostate cancer patients</title><title>Experimental oncology</title><addtitle>Exp Oncol</addtitle><description>To compare cancer-specific survival rates for familial and sporadic prostate cancer patients.
Gleason score and age at diagnosis of familial group and sporadic group were compared by χ(2) and t-test. Cancer-specific survival rates were analyzed by the Kaplan - Meier method and compared by log-rank test. Statistically significant level was set at p < 0.05.
Among 1175 prostate cancer patients, familial group consisted of 215 (18.3%) patients, the sporadic group consisted of 960 (81.7%) patients. The familial group patient's mean age at diagnosis (58.9 years old, 95% confidence interval (CI) 57.8-60.1) was significantly younger than that of sporadic group patients (67.2 years old, 95% CI 66.7-67.6) (p < 0.0001). Comparing Gleason score between familial group and sporadic group revealed no statistically significant difference. The analysis showed that 92% (95% CI 0.88-0.97) of familial group patients had a 10-year cancer-specific survival rates, which was a significantly better outcome than that of sporadic group with 69% (95% CI 0.60-0.78) 10-year cancer-specific survival rates (p = 0.0237).
The study data demonstrate statistically significant difference between familial group and sporadic group concerning age and cancer-specific survival rates, but not Gleason score.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prostatic Neoplasms - mortality</subject><issn>1812-9269</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j8tKBDEURLNQnHH0FyRLNw15J3enDL5gwIW6bjLpG4j0yyQ94N_boK4KDoei6oxsueOiAWFgQy5L-WTMaDDqgmyE4VyAMlty97bkUzr5nmZfsdAp0uiH1KeV-LGjZZ6y71Kgc55KXRUa_Bgw09nXhGMtV-Q8-r7g9V_uyMfjw_v-uTm8Pr3s7w_NzIWpjVeOg8COW6c1RpQOVJDAnI2WSa6CsFZjABHRBiMCZ0w720U4KhdXKnfk9rd3HfK1YKntkErAvvcjTktpuQGuQToHq3rzpy7HAbt2zmnw-bv9fy1_ADhjUcc</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Plonis, J</creator><creator>Nakazawa-Miklasevica, M</creator><creator>Malevskis, A</creator><creator>Vaganovs, P</creator><creator>Pildava, S</creator><creator>Vjaters, E</creator><creator>Gardovskis, J</creator><creator>Miklasevics, E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201506</creationdate><title>Survival rates of familial and sporadic prostate cancer patients</title><author>Plonis, J ; Nakazawa-Miklasevica, M ; Malevskis, A ; Vaganovs, P ; Pildava, S ; Vjaters, E ; Gardovskis, J ; Miklasevics, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-a48192ed17855efe3894c39087f70314c2775ec92fe7c62c100587df9b48f92f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prostatic Neoplasms - mortality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Plonis, J</creatorcontrib><creatorcontrib>Nakazawa-Miklasevica, M</creatorcontrib><creatorcontrib>Malevskis, A</creatorcontrib><creatorcontrib>Vaganovs, P</creatorcontrib><creatorcontrib>Pildava, S</creatorcontrib><creatorcontrib>Vjaters, E</creatorcontrib><creatorcontrib>Gardovskis, J</creatorcontrib><creatorcontrib>Miklasevics, E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Plonis, J</au><au>Nakazawa-Miklasevica, M</au><au>Malevskis, A</au><au>Vaganovs, P</au><au>Pildava, S</au><au>Vjaters, E</au><au>Gardovskis, J</au><au>Miklasevics, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival rates of familial and sporadic prostate cancer patients</atitle><jtitle>Experimental oncology</jtitle><addtitle>Exp Oncol</addtitle><date>2015-06</date><risdate>2015</risdate><volume>37</volume><issue>2</issue><spage>154</spage><epage>155</epage><pages>154-155</pages><issn>1812-9269</issn><abstract>To compare cancer-specific survival rates for familial and sporadic prostate cancer patients.
Gleason score and age at diagnosis of familial group and sporadic group were compared by χ(2) and t-test. Cancer-specific survival rates were analyzed by the Kaplan - Meier method and compared by log-rank test. Statistically significant level was set at p < 0.05.
Among 1175 prostate cancer patients, familial group consisted of 215 (18.3%) patients, the sporadic group consisted of 960 (81.7%) patients. The familial group patient's mean age at diagnosis (58.9 years old, 95% confidence interval (CI) 57.8-60.1) was significantly younger than that of sporadic group patients (67.2 years old, 95% CI 66.7-67.6) (p < 0.0001). Comparing Gleason score between familial group and sporadic group revealed no statistically significant difference. The analysis showed that 92% (95% CI 0.88-0.97) of familial group patients had a 10-year cancer-specific survival rates, which was a significantly better outcome than that of sporadic group with 69% (95% CI 0.60-0.78) 10-year cancer-specific survival rates (p = 0.0237).
The study data demonstrate statistically significant difference between familial group and sporadic group concerning age and cancer-specific survival rates, but not Gleason score.</abstract><cop>Ukraine</cop><pmid>26112946</pmid><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1812-9269 |
| ispartof | Experimental oncology, 2015-06, Vol.37 (2), p.154-155 |
| issn | 1812-9269 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1691593889 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Humans Kaplan-Meier Estimate Male Middle Aged Prostatic Neoplasms - mortality |
| title | Survival rates of familial and sporadic prostate cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T23%3A25%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20rates%20of%20familial%20and%20sporadic%20prostate%20cancer%20patients&rft.jtitle=Experimental%20oncology&rft.au=Plonis,%20J&rft.date=2015-06&rft.volume=37&rft.issue=2&rft.spage=154&rft.epage=155&rft.pages=154-155&rft.issn=1812-9269&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1691593889%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1691593889&rft_id=info:pmid/26112946&rfr_iscdi=true |